What oral acyclovir dosing is recommended for treating HSV-related mouth sores in an otherwise healthy adult, for both primary infection and recurrent lesions?

Acyclovir for Mouth Sores (HSV Gingivostomatitis/Herpes Labialis)

For mild HSV-related mouth sores in otherwise healthy adults, treat with oral acyclovir 400 mg three times daily for 5–10 days, starting as early as possible during the prodrome or at first sign of lesions. 1

Primary (First Episode) Oral HSV Infection

For a true first clinical episode of oral HSV (gingivostomatitis), use acyclovir 200 mg orally 5 times daily for 7–10 days or until complete clinical resolution. 2 This longer duration and higher frequency dosing is critical because primary infections are typically more severe and prolonged than recurrences.

• The FDA-approved dosing for initial genital herpes (which applies to mucocutaneous HSV) is 200 mg five times daily for 10 days, and this regimen has been shown to reduce healing time by 50% and stop viral shedding 90% sooner. 3
• Alternative dosing for primary infection: Acyclovir 400 mg orally 5 times daily for 10 days can also be used for first-episode herpes proctitis and may be extrapolated to severe oral disease. 2
• For moderate-to-severe gingivostomatitis that impairs oral intake, start with IV acyclovir 5–10 mg/kg every 8 hours, then switch to oral therapy once lesions begin to regress; continue until complete healing. 1

Recurrent Oral HSV (Herpes Labialis)

For recurrent herpes labialis in immunocompetent adults, use acyclovir 400 mg orally three times daily for 3–5 days, initiated at the first prodromal symptom or within 24 hours of lesion onset. 4 This regimen is supported by randomized controlled trials showing reduced lesion duration when treatment begins early.

• Alternative recurrent dosing options from CDC guidelines include: 2
  • Acyclovir 200 mg orally 5 times daily for 5 days
  • Acyclovir 800 mg orally twice daily for 5 days
• Valacyclovir (a prodrug of acyclovir with better bioavailability) is approved at 1 g orally twice daily for adults and adolescents with mucocutaneous HSV. 1 Short-course valacyclovir (2 g twice daily for 1 day) has also shown efficacy in reducing healing time. 5
• Famciclovir 500 mg orally twice daily is another alternative for adults, though no pediatric formulation exists. 1

Key Timing Consideration

• Treatment must begin within 48–72 hours of symptom onset to achieve meaningful clinical benefit; the earlier, the better. 4 Patients who delay treatment beyond this window derive minimal benefit from antivirals in recurrent disease. 2

Duration of Therapy: A Critical Pitfall

Do not automatically stop acyclovir at day 5 if lesions have not completely healed. 6 The 5-day regimen is a minimum; therapy should continue until all lesions are fully crusted and healed. 6

• If lesions show partial improvement at day 5, verify adherence and continue the same dose until complete resolution. 6
• If lesions persist beyond 7 days or worsen despite appropriate therapy, consider:
  • Misdiagnosis (the episode may actually be a first infection requiring 7–10 days)
  • Poor adherence or inadequate dosing
  • Possible acyclovir resistance (rare in immunocompetent patients but must be ruled out) 6, 7

Suppressive Therapy for Frequent Recurrences

For patients with ≥6 recurrences per year, initiate daily suppressive acyclovir 400 mg orally twice daily. 2 This reduces recurrence frequency by at least 75%. 2, 4

• Suppressive therapy has been documented as safe and effective for up to 5 years. 2
• After 1 year of continuous suppression, discontinue acyclovir to reassess the patient's natural recurrence rate. 2
• Alternative suppressive regimen: Acyclovir 200 mg orally 3–5 times daily, titrated to the lowest dose that prevents recurrences. 2
• Suppressive acyclovir (200 mg four times daily) effectively prevented recurrences in 9 of 11 patients with frequent non-genital HSV in a placebo-controlled trial. 8

Prophylaxis for Trigger-Related Recurrences

For patients with UV light–triggered herpes labialis, use sunscreen (SPF ≥15) alone or combined with acyclovir 400 mg orally 2–3 times daily. 4 Sunscreen is highly effective as monotherapy for UV-induced recurrences.

Special Populations: Immunocompromised Patients

In immunocompromised adults (HIV, transplant recipients, chemotherapy, chronic corticosteroids), increase oral acyclovir to 400 mg 3–5 times daily and treat for longer durations until complete healing. 6

• Early IV therapy (acyclovir 5–10 mg/kg every 8 hours) is recommended for extensive lesions, inability to take oral medication, or lack of response to oral therapy. 6
• Acyclovir resistance occurs in 10–30% of immunocompromised patients, especially transplant recipients. 6, 7 If lesions do not improve after 7 days of appropriate therapy, obtain viral culture with drug susceptibility testing or PCR with genotypic resistance testing. 6
• For confirmed acyclovir-resistant HSV: Switch to foscarnet 40 mg/kg IV every 8 hours (or 60 mg/kg IV every 12 hours) for 10 days or until lesions heal. 1, 6 Monitor for nephrotoxicity and electrolyte disturbances during foscarnet therapy. 6

Topical Acyclovir: Not Recommended

Topical acyclovir is substantially less effective than oral therapy and should not be used. 2 While 5% acyclovir cream may modestly reduce lesion duration if applied very early, systemic therapy is markedly superior. 4, 3

Common Pitfalls to Avoid

• Stopping therapy prematurely (at day 5) while lesions are still active leads to prolonged disease. 6
• Assuming every episode is recurrent: Some apparent "recurrences" are actually the first clinical episode and require 7–10 days of treatment, not 5 days. 6
• Delaying resistance testing in immunocompromised patients; obtain culture with susceptibility testing promptly if lesions persist beyond 7 days. 6
• Using topical acyclovir alone instead of oral therapy. 2, 4
• Failing to assess immune status (HIV, transplantation, chemotherapy, chronic steroids) before deciding on treatment intensity. 6

Dosing Adjustments

• Renal impairment: Acyclovir half-life and total body clearance depend on renal function; dosage reduction is required in patients with reduced creatinine clearance. 9
• Geriatric patients: Acyclovir plasma concentrations are higher due to age-related renal decline; dose reduction may be necessary. 9
• Food: Acyclovir tablets may be administered with or without food, as food does not affect absorption. 9

When to Hospitalize and Use IV Acyclovir

• Severe oral disease preventing oral intake
• Disseminated HSV infection (hepatitis, pneumonitis, encephalitis)
• Progressive disease in immunocompromised patients despite oral therapy
• Suspected or confirmed acyclovir resistance requiring foscarnet

All above situations warrant IV acyclovir 5–10 mg/kg every 8 hours for 5–7 days or until clinical resolution. 2, 6